Hard to Treat Diseases and its China subsidiary Mellow Hopeannounce, that the first shipment of H1N1 Influenza A Vaccine for Chileanmarket had been agreed upon with the Chilean government. Mellow Hope alreadyapplied for the export license and the vaccine will ship shortly.Earlier this week the Chilean Institute of Public Health issued the Registration Certificate for Mellow Hope'sH1N1 Influenza A Vaccine (Virion Split) The government tenders the bid in thescope of 4 to 6 million doses and had already secured the first order of200,000 doses. This vaccine, worth approximately $1.8 million USD, will shipto the Chilean private market HTDS' CEO Terry Yuan said "The Government of Chile showed a great agilityin the fight against the H1N1. The Government does everything in its power toassure the safety of Chilean citizens and the vaccine negotiations had beenexemplary ones." Mr. Yuan said further "Yes, the first 200,000 doses had beenscheduled, but the final number tendered by the government is somewherebetween 4 to 6 million doses. The final figures still need be worked out withthe Chilean health authorities, but this is a tremendous start to our SouthAmerican Expansion and we are looking forward to work with other governmentsin this region." Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europeand Mainland China. HTDS is a parent company with operations in East EuropeanSerbia based pharmaceutical company Slavica Bio Chem Co and in China MellowHope Inc.